AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34560137
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with standard therapy (cyclophosphamide/azathioprine or mycophenolate mofetil)
Trial: 34069621
Drug: Group multicomponent
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group multicomponent cognitive‐behavioral therapy
Trial: 33983051
Drug: Zelesse cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zelesse cream (monotherapy for non-infectious VV)
Trial: 33983051
Drug: Zelesse cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zelesse cream (adjuvant to antimicrobial therapy for infectious VV)
Trial: 35784687
Drug: Withania somnifera
RxNorm normalized name: WITHANIA SOMNIFERA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withania somnifera (WS) root capsules, given twice a day for 12 weeks
Trial: 35784687
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch capsules), given twice a day for 12 weeks
Trial: 35126900
Drug: Early enteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early enteral nutrition (EEN) support combined with chemotherapy
Trial: 33031833
Drug: Bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (400 mg once daily for 21 days)
Trial: 34046892
Drug: Topical Epigallocatechin-3-gallate
RxNorm normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Epigallocatechin-3-gallate (EGCG)
Trial: 34523740
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol treatment (800 ?g single dose)
Trial: 38200581
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg daily)
Trial: 32349927
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) plus docetaxel and estramustine (DE)
Trial: 39475860
Drug: Multi-Ingredient Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-Ingredient Supplement (MIS)
Trial: 33880554
Drug: Specialized nutritious
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized nutritious food (SNF) treatment (1 of 4 types: 3 fortified-blended foods or a lipid-based nutrient supplement)
Trial: 35584475
Drug: Wheelchair basketball
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheelchair basketball (2 hours, twice a week for 12 months)
Trial: 34228837
Drug: Candesartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan treatment in the DIRECT-Protect trials
Trial: 34048061
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (660 nm 200 mW CW applied at a distance of 1 cm to 4 points on the occlusal area, and 810 nm 200 mW CW applied at tissue surface at three points on the buccal and three points on the lingual gingiva for 15 seconds)
Trial: 33514571
Drug: Leucine-rich protein
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-rich protein supplement
Trial: 34844061
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted manual-assisted problem-solving training (C-MAP) plus treatment as usual (TAU)
Trial: 32977969
Drug: Cardioplegia with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioplegia with diazoxide (500 μmol/L)
Trial: 36125279
Drug: Ubrogepant 25
RxNorm normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ubrogepant 25 mg
Trial: 32073660
Drug: Ubrogepant 50
RxNorm normalized name: ubrogepant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubrogepant 50 mg (pooled)
Trial: 35569466
Drug: PBRT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBRT alone (64.8–70.2 Gy at 1.8 Gy per fraction daily)
Trial: 34173988
Drug: Photobiomodulation (PBM.G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM.G)
Trial: 34173988
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C.G)
Trial: 35701067
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil (one time per day) and placebo (one time per day)
Trial: 35701067
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil (two times per day)
Trial: 34636057
Drug: Topical glycopyrronium
RxNorm normalized name: glycopyrronium Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glycopyrronium tosylate 3.75%
Trial: 34636057
Drug: Topical glycopyrronium
RxNorm normalized name: glycopyrronium Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glycopyrronium tosylate 2.5%
Trial: 35034478
Drug: Glucocorticoid, immunosuppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid, immunosuppressant and other drugs (Control Group)
Trial: 36507329
Drug: H2 inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 inhalation therapy
Trial: 36507329
Drug: Control (air
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (air inhalation)
Trial: 36350049
Drug: Tobacco treatment
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco treatment intervention offered during lung cancer screening at multiple clinical timepoints (RP1, RP2, RP3)
Trial: 32719050
Drug: Online evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online evidence-based medicine (EBM) supplement
Trial: 34428646
Drug: Hydroxy selenomethionine
RxNorm normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxy selenomethionine (OH‐SeMet) supplementation at 0.2, 0.4, 0.6, and 0.8 mg/kg
Trial: 34428646
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 0.0 mg/kg Se
Trial: 32201122
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (steroid)
Trial: 32201122
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer solution (placebo)
Trial: 34835970
Drug: Zinc deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc deficiency defined as serum Zn concentration <9.9 µmol/L
Trial: 616082294
Drug: New high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New high viscosity formula (OGD, Refresh Optive Gel Drops, Allergan)
Trial: 616082294
Drug: Systane Gel
RxNorm normalized name: PEG-400/Propylene Glycol 0.4%-0.3% Ophthalmic Solution [SYSTANE GEL DROPS]
DrugBank: Lanolin (DB11112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systane Gel Drops (SGD, Alcon)
Trial: 616082294
Drug: Genteal Lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genteal Lubricant Gel Drops (GGD, Novartis)
Trial: 34330043
Drug: 3-lesson unguided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-lesson unguided online treatment program targeting rumination and worry
Trial: 34108036
Drug: Medication monitor
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication monitor reminders and differentiated care (Wisepill evriMED 1000)
Trial: 34108036
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (medication monitors for adherence tracking, TB education, normal clinic follow-up)
Trial: 33252635
Drug: Erbium-YAG laser
RxNorm normalized name: erbium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erbium-YAG laser treatment
Trial: 33833857
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality (VR) treatment
Trial: 35241087
Drug: SHR3680 (80mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR3680 (80mg, 160mg, 240mg daily)
Trial: 35241087
Drug: SHR3680 (40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR3680 (40mg to 480mg daily)
Trial: 32716589
Drug: Delayed-loaded implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-loaded implants
Trial: 33960504
Drug: Oral paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral paclitaxel 615 mg/m2 with encequidar 15 mg
Trial: 33960504
Drug: Intravenous paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous paclitaxel 80 mg/m2
Trial: 34957952
Drug: 5 drops
RxNorm normalized name: Bifidobacterium animalis 1 billion cell/5 drops ORAL DROPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 drops of oral synbiotic daily along with phototherapy
Trial: 34787778
Drug: Afatinib 30
RxNorm normalized name: afatinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 30 mg with daily TMZ and RT
Trial: 34787778
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg with RT alone
Trial: 32970697
Drug: Daily self-administered
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-administered vaginal progesterone (VP)
Trial: 33866656
Drug: Any treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any treatment received
Trial: 37380728
Drug: Dapagliflozin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin plus basal‐bolus insulin (DAPA group)
Trial: 37380728
Drug: Basal‐bolus insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal‐bolus insulin alone (INSULIN group)
Trial: 34197281
Drug: V-01 vaccine
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: V-01 vaccine (10, 25, and 50 µg)
Trial: 34197281
Drug: V-01 vaccine
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: V-01 vaccine (10 µg) subgroup and elderly participants
Trial: 32369298
Drug: Topical spray
RxNorm normalized name: Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical spray of papaverine on harvested LIMA
Trial: 32369298
Drug: Perivascular injection
RxNorm normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perivascular injection of papaverine
Trial: 36681255
Drug: Revefenacin 175
RxNorm normalized name: REVEFENACIN 175MCG/3ML INHL SOLN 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revefenacin 175 μg
Trial: 32158738
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment with biopsychosocial perceived etiology
Trial: 32158738
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment with biopsychosocial perceived etiology
Trial: 32158738
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment with biomedical perceived etiology
Trial: 32158738
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment with biomedical perceived etiology
Trial: 32158738
Drug: Treatment information
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment information wording matching perceived etiology
Trial: 36216984
Drug: Parent–Child Interaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent–Child Interaction Therapy‐Emotion Development (PCIT‐ED)
Trial: 33967202
Drug: Gemcitabine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine maintenance therapy
Trial: 32888121
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control with antiarrhythmic drugs (AADs)
Trial: 32785213
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg BNT162b1
Trial: 32815416
Drug: Therapeutic-dose anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose anticoagulation with low-molecular-weight heparin or unfractionated heparin
Trial: 35923359
Drug: Short-term oxygen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term oxygen therapy (STOT)
Trial: 35923359
Drug: Short-term oxygen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term oxygen therapy (STOT) for more than one month or repeated prescriptions
Trial: 32024447
Drug: Internet self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internet self-help blended with face-to-face therapy
Trial: 35442766
Drug: Tislelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab (200 mg every 3 weeks)
Trial: 34973513
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan)
Trial: 32404437
Drug: Intramuscular gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular gentamicin
Trial: 32045103
Drug: PRGF‐gel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRGF‐gel treatment
Trial: 35293287
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus brivaracetam 100 mg
Trial: 35293287
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion brivaracetam 100 mg
Trial: 35293287
Drug: Oral reference
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral reference tablet brivaracetam 100 mg
Trial: 33606908
Drug: iGlarLixi once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iGlarLixi once daily
Trial: 33606908
Drug: BIAsp 30
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BIAsp 30 twice daily
Trial: 35844458
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 7% sevoflurane and intravenous infusion of remifentanil
Trial: 35844458
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 7% sevoflurane
Trial: 32854761
Drug: Guideline therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline therapy plus TCMR (acupressure therapy and Liu Zi Jue Qigong exercises)
Trial: 32854761
Drug: Guideline therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline therapy (control group)
Trial: 33798466
Drug: Volanesorsen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volanesorsen (300 mg subcutaneously once a week for 26 weeks, then every 2 weeks)
Trial: 33798466
Drug: Placebo (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.5 mL subcutaneously once a week for 26 weeks, then every 2 weeks)
Trial: 33137579
Drug: SPEEDI intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPEEDI intervention (10 therapy sessions until 3 months' corrected age, 5 hospital sessions and 5 home-based sessions)
Trial: 36484441
Drug: 10-μg TAK-426
RxNorm normalized name: immunoglobulin G, human 10 % Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-μg TAK-426 vaccine
Trial: 33858553
Drug: Empiric antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antibiotics for MRSA infection
Trial: 33858553
Drug: Non-MRSA antibiotics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-MRSA antibiotics
Trial: 34614379
Drug: Liquid MenACWY-CRM
RxNorm normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid MenACWY-CRM vaccine presentation stored for approximately 24 months
Trial: 34614379
Drug: Liquid MenACWY-CRM
RxNorm normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid MenACWY-CRM vaccine presentation stored for approximately 30 months
Trial: 34614379
Drug: Licensed lyophilized/liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed lyophilized/liquid MenACWY-CRM vaccine presentation
Trial: 33887722
Drug: 1-Step COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-Step COVID-19 Test for total antibodies
Trial: 34778734
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) PEP (400/100 mg) twice daily for 5 days
Trial: 35987857
Drug: Expert assessment
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expert assessment of shoulder impairments followed by an individualised treatment plan
Trial: 35648426
Drug: EGCG solution
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG solution (660 μmol/L)
Trial: 34365061
Drug: Propolis (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis (500 mg/day)
Trial: 32128877
Drug: Low-dose SIM
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SIM (200 mg)
Trial: 32128877
Drug: High-dose SIM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose SIM (1200 mg)
Trial: 34453358
Drug: guselkumab 200
RxNorm normalized name: guselkumab 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 200 mg
Trial: 34453358
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg (after placebo)
Trial: 34453358
Drug: guselkumab 200
RxNorm normalized name: guselkumab 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 200 mg (after placebo)
Trial: 35875346
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic tablets (500 mg, 2 tab/day)
Trial: 32182098
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus the codesigned education video delivered via a handheld tablet device at discharge
Trial: 34628152
Drug: Multimodal program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal program including mindfulness-based practices, expressive arts, and EMDR group treatment
Trial: 32575124
Drug: Tocilizumab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (400 mg dose)
Trial: 37232393
Drug: Non-statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-statin therapy
Trial: 35533197
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.125 M L‐glutamic acid at 1.65 mL/kg/h
Trial: 35533197
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.125 M L‐glutamic acid at 1.65 mL/kg/h (in patients without diabetes)
Trial: 35533197
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.125 M L‐glutamic acid
Trial: 32191400
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 IU twice daily
Trial: 35045999
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy alone (HFNO or standard oxygen)
Trial: 34731916
Drug: Postoperative Hb
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative Hb < 10 g/dl
Trial: 32557305
Drug: Risk-based quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-based quality management approach in clinical trials with combination products
Trial: 32557305
Drug: Combination products
RxNorm normalized name: Other cardiac combination products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination products in clinical trials
Trial: 33196289
Drug: Paraffin bath
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin bath therapy
Trial: 33606023
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic therapy with comprehensive EPC service referral
Trial: 33606023
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic therapy without EPC